Business Context and Reporting Period
This Form 8-K is filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) for the reporting period of September 1, 2016. The filing addresses a corporate governance event involving the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding personnel changes and does not contain financial statements.
Material Changes
- Board Resignation: Leah Rush Cann resigned from the Board of Directors effective September 1, 2016.
- Reason for Departure: The resignation follows her appointment as Managing Director and Senior Biotechnology Analyst at Oppenheimer & Co. Inc.
- Board Size Adjustment: Following the resignation, the Board decided to reduce its size to seven directors.
- No Disagreement: The filing explicitly states the resignation is not the result of any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies related to the resignation were disclosed beyond the standard statement that the departure was amicable.
Investor Verification Checklist
- Verify the current composition of the Board of Directors to confirm the reduction to seven members.
- Confirm whether a new director has been appointed to replace Leah Rush Cann or if the Board intends to operate with seven members indefinitely.
- Review subsequent filings to ensure no undisclosed disagreements or related party transactions exist regarding the departure.